Paclitaxel-PHBV nanoparticles and their toxicity to endometrial and primary ovarian cancer cells

Biomaterials

Volumn 34, Issue 16, 2013, Pages 4098-4108

  Vilos, Cristian ^a,b   Morales, Francisco A ^a   Solar, Paula A ^a   Herrera, Natalia S ^a   Gonzalez Nilo, Fernando D ^a   Aguayo, Daniel A ^a   Mendoza, Hegaly L ^a   Comer, Jeffrey ^a,g   Bravo, Maria L ^c   Gonzalez, Pamela A ^c   Kato, Sumie ^d   Cuello, Mauricio A ^d   Alonso, Catalina ^e   Bravo, Erasmo J ^e   Bustamante, Eva I ^f   Owen, Gareth I ^c   Velasquez, Luis A ^a,b  

^a UNIVERSIDAD ANDRÉS BELLO   (Chile)

^b CENTER FOR THE DEVELOPMENT OF NANOSCIENCE AND NANOTECHNOLOGY CEDENNA   (Chile)

^c PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

^d PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

^e Hospital Dr Gustavo Fricke   (Chile)

^f Fundacion Arturo Lopez Perez   (Chile)

^g Centro de Innovación UC Anacleto Angelini   (Chile)

Author keywords

Drug delivery; Molecular dynamics simulations; Nanoparticle; Ovarian cancer; Paclitaxel; PHBV

Indexed keywords

MOLECULAR DYNAMICS SIMULATIONS; MOLECULAR SIMULATIONS; OVARIAN CANCER CELLS; OVARIAN CANCERS; PACLITAXEL; PHARMACEUTICAL PRODUCTION; PHBV; PHYSICO-CHEMICAL CHARACTERIZATION;

CELL CULTURE; CELL DEATH; CHEMICAL MODIFICATION; DRUG DELIVERY; FLOW CYTOMETRY; FOURIER TRANSFORM INFRARED SPECTROSCOPY; MOLECULAR BIOLOGY; MOLECULAR DYNAMICS; MOLECULAR STRUCTURE; POLYMERS; TOXICITY; TRANSMISSION ELECTRON MICROSCOPY;

NANOPARTICLES;

NANOPARTICLE; PACLITAXEL; POLY(3 HYDROXYBUTYRIC ACID CO HYDROXYVALERIC ACID); UNCLASSIFIED DRUG; VALERIC ACID DERIVATIVE;

ARTICLE; CANCER CELL CULTURE; CANCER PATIENT; CELL DEATH; CELL ISOLATION; CHEMICAL MODIFICATION; CONFOCAL MICROSCOPY; CONTROLLED STUDY; CYTOTOXICITY; ENDOCYTOSIS; ENDOMETRIUM CANCER; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN TISSUE; INFRARED SPECTROSCOPY; LARGE SCALE PRODUCTION; MOLECULAR MODEL; OVARY CANCER; PHYSICAL CHEMISTRY; PRIMARY CELL CULTURE; PRIMARY TUMOR; PRIORITY JOURNAL; TRANSMISSION ELECTRON MICROSCOPY;

CELL DEATH; ENDOMETRIAL NEOPLASMS; FEMALE; G2 PHASE CELL CYCLE CHECKPOINTS; HUMANS; M PHASE CELL CYCLE CHECKPOINTS; MICROSCOPY, FLUORESCENCE; NANOPARTICLES; OVARIAN NEOPLASMS; OXAZINES; PACLITAXEL; PARTICLE SIZE; POLYESTERS; SPECTROSCOPY, FOURIER TRANSFORM INFRARED; STATIC ELECTRICITY; TIME FACTORS; TUMOR CELLS, CULTURED; WATER;

EID: 84874957622     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2013.02.034     Document Type: Article

References (41)

1. Jemal A., Siegel R., Xu J., Ward E. Cancer statistics. CA Cancer J Clin 2010, 2010(60):277-300.
2. Bast R.C., Hennessy B., Mills G.B. The biology of ovarian cancer: new opportunities for translation. Nat Rev Cancer 2009, 9:415-428.
3. Vaughan S., Coward J.I., Bast R.C., Berchuck A., Berek J.S., Brenton J.D., et al. Rethinking ovarian cancer: recommendations for improving outcomes. Nat Rev Cancer 2011, 11:719-725.
4. Arias J.L. Drug targeting strategies in cancer treatment: an overview. Mini Rev Med Chem 2011, 11:1-17.
5. Wang A.Z., Langer R., Farokhzad O.C. Nanoparticle delivery of cancer drugs. Annu Rev Med 2012, 63:185-198.
6. Wagner V., Dullaart A., Bock A.K., Zweck A. The emerging nanomedicine landscape. Nat Biotechnol 2006, 24:1211-1217.
7. Dhar S., Kolishetti N., Lippard S.J., Farokhzad O.C. Targeted delivery of a cisplatin prodrug for safer and more effective prostate cancer therapy in vivo. Proc Natl Acad Sci USA 2011, 108:1850-1855.
8. Shi J., Xiao Z., Votruba A.R., Vilos C., Farokhzad O.C. Differentially charged hollow core/shell lipid-polymer-lipid hybrid nanoparticles for small interfering RNA delivery. Angew Chem Int Ed Engl 2011, 50:7027-7031.
9. Wohlfart S., Gelperina S., Kreuter J. Transport of drugs across the blood-brain barrier by nanoparticles. J Control Release 2012, 161:264-273.
10. Xie J., Liu G., Eden H.S., Ai H., Chen X. Surface-engineered magnetic nanoparticle platforms for cancer imaging and therapy. Acc Chem Res 2011, 44:883-892.
11. Kumari A., Yadav S.K., Yadav S.C. Biodegradable polymeric nanoparticles based drug delivery systems. Colloids Surf B Biointerfaces 2010, 75:1-18.
12. Cragg G.M., Newman D.J. A tale of two tumor targets: topoisomerase I and tubulin. The Wall and Wani contribution to cancer chemotherapy. J Nat Prod 2004, 67:232-244.
13. Acharya S., Sahoo S.K. PLGA nanoparticles containing various anticancer agents and tumour delivery by EPR effect. Adv Drug Deliv Rev 2011, 63:170-183.
14. Slater S., Mitsky T.A., Houmiel K.L., Hao M., Reiser S.E., Taylor N.B., et al. Metabolic engineering of Arabidopsis and Brassica for poly(3-hydroxybutyrate-co-3-hydroxyvalerate) copolymer production. Nat Biotechnol 1999, 17:1011-1016.
15. Kuppan P., Vasanthan K.S., Sundaramurthi D., Krishnan U.M., Sethuraman S. Development of poly(3-hydroxybutyrate-co-3-hydroxyvalerate) fibers for skin tissue engineering: effects of topography, mechanical, and chemical stimuli. Biomacromolecules 2011, 12:3156-3165.
16. Sendil D., Gursel I., Wise D.L., Hasirci V. Antibiotic release from biodegradable PHBV microparticles. J Control Release 1999, 59:207-217.
17. Vilos C., Velasquez L.A. Therapeutic strategies based on polymeric microparticles. J Biomed Biotechnol 2012, 2012:672760.
18. Vilos C., Constandil L., Herrera N., Solar P., Escobar-Fica J., Velasquez L.A. Ceftiofur-loaded PHBV microparticles: a potential formulation for a long-acting antibiotic to treat animal infections. Electron J Biotechnol 2012, 15:1-13.
19. Sahana B., Santra K., Basu S., Mukherjee B. Development of biodegradable polymer based tamoxifen citrate loaded nanoparticles and effect of some manufacturing process parameters on them: a physicochemical and in-vitro evaluation. Int J Nanomedicine 2010, 5:621-630.
20. Mao S., Xu J., Cai C., Germershaus O., Schaper A., Kissel T. Effect of WOW process parameters on morphology and burst release of FITC-dextran loaded PLGA microspheres. Int J Pharm 2007, 334:137-148.
21. Zhang S.Q., Chen G.H. Determination of paclitaxel in human plasma by UPLC-MS-MS. J Chromatogr Sci 2008, 46:220-224.
22. Vanommeslaeghe K., Hatcher E., Acharya C., Kundu S., Zhong S., Shim J., et al. CHARMM general force field: a force field for drug-like molecules compatible with the CHARMM all-atom additive biological force fields. J Comput Chem 2010, 31:671-690.
23. Phillips J.C., Braun R., Wang W., Gumbart J., Tajkhorshid E., Villa E., et al. Scalable molecular dynamics with NAMD. J Comput Chem 2005, 26:1781-1802.
24. Wells D.B., Bhattacharya S., Carr R., Maffeo C., Ho A., Comer J., et al. Optimization of the molecular dynamics method for simulations of DNA and ion transport through biological nanopores. Methods Mol Biol 2012, 870:165-186.
25. Darve E., Rodriguez-Gomez D., Pohorille A. Adaptive biasing force method for scalar and vector free energy calculations. J Chem Phys 2008, 128:144120.
26. Henin J., Fiorin G., Chipot C., Klein M. Exploring multidimensional free energy landscapes using time-dependent biases on collective variables. J Chem Theory Comput 2009, 6:35-47.
27. Marrink S.J., Risselada H.J., Yefimov S., Tieleman D.P., de Vries A.H. The MARTINI force field: coarse grained model for biomolecular simulations. J Phys Chem B 2007, 111:7812-7824.
28. Hess B., Kutzner C., Van Der Spoel D., Lindahl E. GROMACS 4: algorithms for highly efficient, load-balanced, and scalable molecular simulation. J Chem Theory Comput 2008, 4:435-447.
29. Bussi G., Donadio D., Parrinello M. Canonical sampling through velocity rescaling. J Chem Phys 2007, 126:014101.
30. Nishida M. The Ishikawa cells from birth to the present. Hum Cell 2002, 15:104-117.
31. Hill B.T., Whelan R.D., Gibby E.M., Sheer D., Hosking L.K., Shellard S.A., et al. Establishment and characterisation of three new human ovarian carcinoma cell lines and initial evaluation of their potential in experimental chemotherapy studies. Int J Cancer 1987, 39:219-225.
32. Kato S., Sadarangani A., Lange S., Delpiano A., Vargas M., Brañes J., et al. 2-methoxyestradiol mediates apoptosis through caspase-dependent and independent mechanisms in ovarian cancer cells but not in normal counterparts. Reprod Sci 2008, 15:878-894.
33. Sadarangani A., Kato S., Espinoza N., Lange S., Llados C., Espinosa M., et al. TRAIL mediates apoptosis in cancerous but not normal primary cultured cells of the human reproductive tract. Apoptosis 2007, 12:73-85.
34. Peer D., Karp J.M., Hong S., Farokhzad O.C., Margalit R., Langer R. Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol 2007, 2:751-760.
35. Nel A.E., Madler L., Velegol D., Xia T., Hoek E.M., Somasundaran P., et al. Understanding biophysicochemical interactions at the nano-bio interface. Nat Mater 2009, 8:543-557.
36. Loverde S.M., Klein M.L., Discher D.E. Nanoparticle shape improves delivery: rational coarse grain molecular dynamics (rCG-MD) of taxol in worm-like PEG-PCL Micelles. Adv Mater 2012, 24:3823-3830.
37. Li H., Chang J. Preparation, characterization and in vitro release of gentamicin from PHBV/wollastonite composite microspheres. J Control Release 2005, 107:463-473.
38. Hunz M., Jetter A., Warm M., Pantke E., Tuscher M., Hempel G., et al. Plasma and tissue pharmacokinetics of epirubicin and Paclitaxel in patients receiving neoadjuvant chemotherapy for locally advanced primary breast cancer. Clin Pharmacol Ther 2007, 81:659-668.
39. Xiao X.Q., Zhao Y., Chen G.Q. The effect of 3-hydroxybutyrate and its derivatives on the growth of glial cells. Biomaterials 2007, 28:3608-3616.
40. Cheng B., Yang X., Chen C., Cheng D., Xu X., Zhang X. D-beta-hydroxybutyrate prevents MPP+induced neurotoxicity in PC12 cells. Neurochem Res 2010, 35:444-451.
41. Hu Z.G., Wang H.D., Jin W., Yin H.X. Ketogenic diet reduces cytochrome c release and cellular apoptosis following traumatic brain injury in juvenile rats. Ann Clin Lab Sci 2009, 39:76-83.